Abstract:Rare variants of the triggering receptor expressed on myeloid cell 2 (TREM2) gene are major risk factors for Alzheimer disease (AD), and drugs targeting the TREM2 protein are being developed. However, it is unknown whether carriers of a TREM2 risk variant have a clinically distinct AD phenotype. Here we studied a full range of clinical measures in a large cohort of TREM2 variant carriers (n=123, 7.8%, i.e., R62H n=66, R47H n=26, T96K n=16, other TREM2 variants n=17) compared to confirmed non-carriers (n=1,459) with biomarker confirmed symptomatic AD from Amsterdam Dementia Cohort. TREM2 variant carriers (mean age at diagnosis 64.4 years (SD 7.1), 54% female) did not show distinct clinical measures of AD at presentation compared to AD patients not carrying a TREM2 variant (mean age at diagnosis 64.4 SD 7.0, 52% female). Specifically, we observed no differences in MMSE, most neuropsychological domains (except visuospatial functioning), MRI scores, CSF biomarkers, and EEG. Also, in an exploratory analysis of neuroimaging measures, including structural MRI (41 ROIs) and Tau-PET scans of four carriers (R62H, R47H, G58A, D87N), TREM2 variant carriers showed similar atrophy patterns and similar abnormal tracer binding compared to non-carriers. Despite not being different at baseline, carriers did show faster cognitive decline in follow-up. Carriers declined 0.63 (SD 0.25) points on the MMSE more per year compared to non-carriers, but there was no difference in the hazard rate of death after diagnosis. Finally, we explored whether specific TREM2 variants are associated with distinct clinical measures compared to the reference group, i.e. non-carriers, within the same cohort. Notably, both R47H and T96K carriers exhibited faster cognitive decline, and R47H carriers even showed an increased rate of death after diagnosis. In contrast to the shared cognitive decline, these variants showed different results for other measures at baseline. This study presents a detailed overview of the clinical measures in AD patients carrying a TREM2 risk variant, and it shows that carriers of TREM2 risk variants cannot be distinguished based on clinical presentation at baseline. However, carriers exhibit a faster global cognitive decline compared to non-carriers. Variant-specific analyses suggest that especially R47H and T96K carriers drive the association of TREM2 variants with faster cognitive decline.

Association Study of the TREM2 Gene and Identification of a Novel Variant in Exon 2 in Iranian Patients with Late-Onset Alzheimer's Disease

Lack of Genetic Association Between TREM2 and Alzheimer’s Disease in East Asian Population

Association of MS4A6A, CD33, and TREM2 gene polymorphisms with the late-onset Alzheimer’s disease

Association study of TREM2 polymorphism rs75932628 with late-onset Alzheimer's disease in Chinese Han population.

Trem2 P.H157y Variant and the Risk of Alzheimer'S Disease: A Meta-Analysis Involving 14,510 Subjects

TREM2 in Alzheimer’s Disease

Triggering Receptor Expressed On Myeloid Cells 2 Variant Is Rare In Late-Onset Alzheimer'S Disease In Han Chinese Individuals

The association of R47H variant in the TREM2 gene and genetic susceptibility to Alzheimer's disease in Serbian population

The Association between TREM2 Gene and Late-Onset Alzheimer’s Disease in Chinese Han Population

Associations Between TREML2 Gene Variants and Alzheimer's Disease: Biomarkers, Neuroimage, and Cognition

Lack of association between triggering receptor expressed on myeloid cells 2 polymorphism rs75932628 and late-onset Alzheimer's disease in a Chinese Han population.

A rare coding variant in TREM2 increases risk for Alzheimer’s disease in Han Chinese (P5.164)

A Rare Coding Variant in TREM2 Increases Risk for Alzheimer's Disease in Han Chinese

TREM2 Variants and Neurodegenerative Diseases: A Systematic Review and Meta-Analysis

A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression

TREM2 Risk Variants with Alzheimer Disease Differ in Rate of Cognitive Decline

The rs75932628 and rs2234253 polymorphisms of the TREM2 gene were associated with susceptibility to frontotemporal lobar degeneration in Caucasian populations

Investigation of rs8106922 and rs157580 of TOMM40 Gene in In-dividuals with Late-Onset Alzheimer’s Disease in Iran

Assessment of TREM2 rs75932628 association with amyotrophic lateral sclerosis in a Chinese population

Triggering Receptor Expressed on Myeloid Cells 2 Variants Are Rare in Parkinson's Disease in a Han Chinese Cohort

Assessment of TREM2 Rs75932628 Association with Parkinson’s Disease and Multiple System Atrophy in a Chinese Population